The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Open accessAbstract
Although multiple sclerosis (MS) is considered to be a CD4, Th17-mediated autoimmune disease, supportive evidence is perhaps circumstantial, often based on animal studies, and is questioned by the perceived failure of CD4-depleting antibodies to control relapsing MS. Therefore, it was interestingly to find that current MS-treatments, believed to act via T cell inhibition, including: beta-interferons, glatiramer acetate, cytostatic agents, dimethyl fumarate, fingolimod, cladribine, daclizumab, rituximab/ocrelizumab physically, or functionally in the case of natalizumab, also depleted CD19+, CD27+ memory B cells. This depletion was substantial and long-term following CD52 and CD20-depletion, and both also induced long-term inhibition of MS with few treatment cycles, indicating induction-therapy activity. Importantly, memory B cells were augmented by B cell activating factor (atacicept) and tumor necrosis factor (infliximab) blockade that are known to worsen MS. This creates a unifying concept centered on memory B cells that is consistent with therapeutic, histopathological and etiological aspects of MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citationA Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Chang, P., Hamlett, A., Musch, B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0902533 · Cited by 1,023
Self-citationTNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,017
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., von Blomberg, B. M. E., Woody, J. N., Hartung, H.-P., & Polman, C. H. (1996) · Neurology · doi:10.1212/wnl.47.6.1531 · Cited by 733
Duddy, M., Niino, M., Adatia, F., Hebert, S., Freedman, M., Atkins, H., Kim, H. J., & Bar-Or, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6092 · Cited by 653
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial
Bar‐Or, A., Calabresi, P. A. J., Arnold, D., Markowitz, C., Shafer, S., Kasper, L. H., Waubant, E., Gazda, S., Fox, R. J., Panzara, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21363 · Cited by 527
Segal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., & Kasper, L. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70173-x · Cited by 479
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Self-citationProinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy
Li, R., Rezk, A., Miyazaki, Y., Hilgenberg, E., Touil, H., Shen, P., Moore, C. S., Michel, L., Althekair, F., Rajasekharan, S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4176 · Cited by 453
Sawcer, S., Franklin, R. J. M., & Ban, M. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70041-9 · Cited by 401
Atkins, H. L., Bowman, M., Allan, D., Anstee, G., Arnold, D. L., Bar-Or, A., Bence-Bruckler, I., Birch, P., Bredeson, C., Chen, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30169-6 · Cited by 325
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Tangye, S. G., Avery, D. T., Deenick, E. K., & Hodgkin, P. D. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.686 · Cited by 301
Kim, S.-H. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.154 · Cited by 295
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
Cox, A. L., Thompson, S. A. J., Jones, J. L., Robertson, V. H., Hale, G., Waldmann, H., Compston, D. A. S., & Coles, A. J. (2005) · European Journal of Immunology · doi:10.1002/eji.200535075 · Cited by 291
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Palanichamy, A., Jahn, S., Nickles, D., Derstine, M., Abounasr, A., Hauser, S. L., Baranzini, S. E., Leppert, D., & von Büdingen, H.-C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400118 · Cited by 289
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
Sorensen, P. S., Lisby, S., Grove, R., Derosier, F., Shackelford, S., Havrdova, E., Drulovic, J., & Filippi, M. (2014) · Neurology · doi:10.1212/wnl.0000000000000125 · Cited by 278
Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination
Rostami, A., & Ciric, B. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.03.002 · Cited by 275
Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
Piccio, L., Naismith, R. T., Trinkaus, K., Klein, R. S., Parks, B. J., Lyons, J. A., & Cross, A. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.99 · Cited by 274
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Kappos, L., Wiendl, H., Selmaj, K., Arnold, D. L., Havrdova, E., Boyko, A., Kaufman, M., Rose, J., Greenberg, S., Sweetser, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501481 · Cited by 265
van Oosten, B. W., Lai, M., Hodgkinson, S., Barkhof, F., Miller, D. H., Moseley, I. F., Thompson, A. J., Rudge, P., McDougall, A., McLeod, J. G., et al. (1997) · Neurology · doi:10.1212/wnl.49.2.351 · Cited by 264
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Thompson, S. A. J., Jones, J. L., Cox, A. L., Compston, D. A. S., & Coles, A. J. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9327-3 · Cited by 232
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
Alping, P., Frisell, T., Novakova, L., Islam‐Jakobsson, P., Salzer, J., Björck, A., Axelsson, M., Malmeström, C., Fink, K., Lycke, J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24651 · Cited by 230
The evidence for a role of B cells in multiple sclerosis
Disanto, G., Morahan, J. M., Barnett, M. H., Giovannoni, G., & Ramagopalan, S. V. (2012) · Neurology · doi:10.1212/wnl.0b013e318249f6f0 · Cited by 220
Self-citationTak, P. P., Thurlings, R. M., Rossier, C., Nestorov, I., Dimic, A., Mircetic, V., Rischmueller, M., Nasonov, E., Shmidt, E., Emery, P., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23178 · Cited by 207
Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Giudice, J. D., Baldassare, A., Schechtman, J., Fudman, E., Kohen, M., Gujrathi, S., Trapp, R. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23732 · Cited by 207
Burt, R. K., Balabanov, R., Han, X., Sharrack, B., Morgan, A., Quigley, K., Yaung, K., Helenowski, I. B., Jovanovic, B., Spahovic, D., et al. (2015) · JAMA · doi:10.1001/jama.2014.17986 · Cited by 200
Autoimmunity during lymphopenia: A two-hit model
Krupica, T., Fry, T. J., & Mackall, C. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.04.569 · Cited by 176
Michel, L., Touil, H., Pikor, N. B., Gommerman, J. L., Prat, A., & Bar-Or, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00636 · Cited by 173
Multiple sclerosis: the environment and causation
Giovannoni, G., & Ebers, G. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32815610c2 · Cited by 168
Self-citationSerafini, B., Severa, M., Columba-Cabezas, S., Rosicarelli, B., Veroni, C., Chiappetta, G., Magliozzi, R., Reynolds, R., Coccia, E. M., & Aloisi, F. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e332ec · Cited by 161
Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis
Komori, M., Blake, A., Greenwood, M., Lin, Y. C., Kosa, P. F., Ghazali, D., Winokur, P. N., Natrajan, M. S., Wuest, S. C., Romm, E., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24408 · Cited by 158
Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety
Hyrich, K. L., Silman, A. J., Watson, K. D., & Symmons, D. P. M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024737 · Cited by 157
Agius, M. A., Kłodowska-Duda, G. A., Maciejowski, M., Potemkowski, A., Li, J., Patra, K., Wesley, J. B., Madani, S., Barron, G., Katz, E., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517740641 · Cited by 150
Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
Martinꝉ, R., Sospedra, M., Rosito, M., & Engelhardt, B. (2016) · European Journal of Immunology · doi:10.1002/eji.201646485 · Cited by 148
Ascherio, A., & Munger, K. L. (2015) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-22822-8_15 · Cited by 134
Phenotypic and functional characterization of human CD25+ B cells
Brisslert, M., Bokarewa, M. I., Larsson, P., Wing, K., Collins, L. V., & Tarkowski, A. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02331.x · Cited by 127
Souto‐Carneiro, M., Mahadevan, V., Takada, K., Fritsch-Stork, R. D. E., Nanki, T., Brown, M. R., Fleisher, T. A., Wilson, M., Goldbach‐Mansky, R. T., & Lipsky, P. E. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2718 · Cited by 125
Giovannoni, G., Cutter, G., Sormani, M. P., Belachew, S. M., Hyde, R., Koendgen, H., Knappertz, V. A., Tomic, D., Leppert, D., Herndon, R. M., et al. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.01.007 · Cited by 118
Self-citationHarp, C. T., Ireland, S. J., Davis, L. S., Remington, G. M., Cassidy, B., Cravens, P. D., Stüve, O., Lovett‐Racke, A. E., Eagar, T. N., Greenberg, B. M., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.201040516 · Cited by 117
Planas, R., Jelčić, I., Schippling, S., Martinꝉ, R., & Sospedra, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201142108 · Cited by 116
van Noort, J. M., Bsibsi, M., Gerritsen, W. H., van der Valk, P., Bajramovic, J. J., Steinman, L., & Amor, S. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e4939c · Cited by 112
Hintzen, R. Q., van Lier, R. A. W., Kuijpers, K. C., et al. (1991) · Journal of Neuroimmunology · doi:10.1016/0165-5728(91)90175-7 · Cited by 100
Li, L., Liu, J., Delohery, T. M., Zhang, D., Arendt, C., & Jones, C. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.10.003 · Cited by 98
Fingolimod treatment promotes regulatory phenotype and function of B cells
Grützke, B., Hucke, S., Groß, C. C., Herold, M. V. B., Posevitz‐Fejfár, A., Wildemann, B., Kieseier, B. C., Dehmel, T., Wiendl, H., & Klotz, L. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.155 · Cited by 95
Blauth, K., Soltys, J. N., Matschulat, A. M., Reiter, C. R., Ritchie, A. M., Baird, N. L., Bennett, J. L., & Owens, G. P. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1500-6 · Cited by 94
Sergott, R. C., Bennett, J. L., Rieckmann, P., Montalbán, X., Mikol, D. D., Freudensprung, U., Plitz, T., & van Beek, J. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.02.019 · Cited by 91
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
Lundy, S. K., Wu, Q., Wang, Q., Dowling, C. A., Taitano, S. H., Mao, G., & Mao‐Draayer, Y. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000211 · Cited by 86
Ireland, S. J., Guzman, A. A., O’Brien, D. E., Hughes, S., Greenberg, B. M., Flores, A., Graves, D. F., Remington, G. M., Frohman, E. M., Davis, L. S., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1472 · Cited by 84
Rizzo, F., Giacomini, E., Mechelli, R., Buscarinu, M. C., Salvetti, M., Severa, M., & Coccia, E. M. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.55 · Cited by 81
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity
Schubert, R. D., Hu, Y., Kumar, G., Szeto, S., Abraham, P., Winderl, J., Guthridge, J. M., Pardo, G., Dunn, J., Steinman, L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402029 · Cited by 78
Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely
Baker, D., & Amor, S. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.05.002 · Cited by 77
Self-citationAdvances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis
Volpe, E., Battistini, L., & Borsellino, G. (2015) · Mediators of Inflammation · doi:10.1155/2015/475158 · Cited by 69
Epstein–Barr virus and multiple sclerosis. From evidence to therapeutic strategies
Menéndez, S. F., Fernández-Morán, M., Fernández‐Vega, I., Pérez-Álvarez, Á. I., & Villafani, J. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.013 · Cited by 68
Ward, E. S., Mittereder, N., Kuta, E. G., Sims, G. P., Bowen, M. A., Dall’Acqua, W. F., Tedder, T. F., Kiener, P. A., Coyle, A. J., Wu, H., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08857.x · Cited by 67
Differential effects of fingolimod on B-cell populations in multiple sclerosis
Nakamura, M., Matsuoka, T., Chihara, N., Miyake, S., Sato, W., Araki, M., Okamoto, T., Lin, Y., Ogawa, M., Murata, M., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514523496 · Cited by 59
von Kutzleben, S., Pryce, G., Giovannoni, G., & Baker, D. (2016) · Immunology · doi:10.1111/imm.12696 · Cited by 57
Self-citationToso, C., Edgar, R. L., Pawlick, R. L., Emamaullee, J. A., Merani, S., Dinyari, P., Mueller, T. F., Shapiro, A. M. J., & Anderson, C. C. (2008) · Transplant International · doi:10.1111/j.1432-2277.2008.00746.x · Cited by 56
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity
Kousin‐Ezewu, O., Azzopardi, L., Parker, R. A., Tuohy, O., Compston, A., Coles, A. J., & Jones, J. (2014) · Neurology · doi:10.1212/wnl.0000000000000520 · Cited by 56
Kannel, K., Alnek, K., Vahter, L., Gross‐Paju, K., Uibo, R., & Kisand, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143393 · Cited by 53
Treating multiple sclerosis with monoclonal antibodies: a 2013 update
Deiß, A., Brecht, I., Haarmann, A., & Buttmann, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.17 · Cited by 53
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
Giovannoni, G., Marta, M., Davis, A., Turner, B. P., Gnanapavan, S., & Schmierer, K. (2016) · Practical Neurology · doi:10.1136/practneurol-2015-001355 · Cited by 50
Self-citationMardiguian, S., Serres, S., Ladds, E. C., Campbell, S. J., Wilainam, P., McFadyen, C., McAteer, M. A., Choudhury, R. P., Smith, P., Saunders, F., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.029 · Cited by 47
Gold, R., Radue, E. W., Giovannoni, G., Selmaj, K. W., Havrdová, E., Stefoski, D., Sprenger, T., Montalbán, X., COHAN, S. L., Umans, K., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0635-y · Cited by 47
Self-citationEffects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica
Graves, J., Vinayagasundaram, U., Mowry, E. M., Matthews, I. R., Marino, J. A., Cheng, J., & Waubant, E. L. (2013) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2013.10.003 · Cited by 40
MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes
Comabella, M., Cantó, E., Nurtdinov, R., Río, J., Villar, L. M., Picón, C., Castilló, J., Fissolo, N., Aymerich, F. X., Auger, C., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv473 · Cited by 40
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
Lin, Y.-C., Winokur, P. N., Blake, A., Wu, T.-X., Romm, E., & Bielekova, B. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.181 · Cited by 39
Hampton, D. W., Serio, A., Pryce, G., Al-Izki, S., Franklin, R. J., Giovannoni, G., Baker, D., & Chandran, S. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-84 · Cited by 34
Self-citationDisease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
Marta, M., & Giovannoni, G. (2012) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152712801661301 · Cited by 33
Self-citationDisease activity return after natalizumab cessation in multiple sclerosis
Rasenack, M., & Derfuss, T. J. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1168295 · Cited by 30
Kap, Y. S., Jagessar, S. A., van Driel, N., Blezer, E. L. A., Bauer, J., van Meurs, M., Smith, P., Laman, J. D., & Hart, B. A. ‘. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9238-3 · Cited by 27
Steinman, L., & Zamvil, S. S. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000317 · Cited by 27
McComish, J. S., Mundy, J., Sullivan, T., Proudman, S., & Hissaria, P. (2014) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12325 · Cited by 25
Teniente‐Serra, A., Grau‐López, L., Mansilla, M. J., Fernández, M. A., Condins, A. E., Ramo-Tello, C. M., & Martínez-Cáceres, E. M. (2016) · Autoimmunity · doi:10.3109/08916934.2016.1138271 · Cited by 25
Heremans, H., Dillen, C., Groenen, M., Matthys, P., & Billiau, A. (1999) · PubMed · Cited by 22
Roll, P., Muhammad, K., Schümann, M., Kleinert, S., & Tony, H.-P. (2012) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2011.645056 · Cited by 17
Asztély, F., Gilland, E., Wattjes, M. P., & Lycke, J. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.04.010 · Cited by 16
Pedotti, R., Musio, S., Scabeni, S., Farina, C., Poliani, P. L., Colombo, E., Costanza, M., Berzi, A., Castellucci, F., Ciusani, E., et al. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.05.010 · Cited by 16
Agahozo, M. C., Peferoen, L. A. N., Baker, D., & Amor, S. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.011 · Cited by 16
Self-citationCombination of TACI-IgG and anti-IL-15 treats murine lupus by reducing mature and memory B cells
Ma, N., He, X., Marrero, B., Chen, X., Wang, X., Zheng, M., Han, G., Chen, G., Hou, C., Shen, B., et al. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.03.017 · Cited by 15
van Nierop, G. P., Janssen, M., Mitterreiter, J. G., van de Vijver, D. A. M. C., de Swart, R. L., Haagmans, B. L., Verjans, G. M. G. M., & Hintzen, R. Q. (2015) · European Journal of Immunology · doi:10.1002/eji.201545921 · Cited by 12
Sargento‐Freitas, J., Morais, R. F., Ribeiro, J. S., Gouveia, A., Nunes, C., Duque, C., Madaleno, J., da Silva, F. A. D. A., Machado, C., Cordeiro, G., et al. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-24 · Cited by 6
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
MacParland, S. A., Liu, J. C., Ma, X.-Z., Innes, B. T., Bartczak, A. M., Gage, B. K., Manuel, J., Khuu, N., Echeverri, J., Linares, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06318-7 · Cited by 1,552
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Ginwala, R., Bhavsar, R., Chigbu, D. G. I., Jain, P., & Khan, Z. K. (2019) · Antioxidants · doi:10.3390/antiox8020035 · Cited by 588
Epstein–Barr virus and multiple sclerosis
Soldan, S. S., & Lieberman, P. M. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00770-5 · Cited by 467
Metadata
- Authors
- Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 16
- Pages
- 41-50
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2584413859
- Cited by
- 289
- References
- 90
- FWCI
- 22.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.